Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002873.SZ Stock Summary
In the News
002873.SZ Financial details
Company Rating
Buy
Market Cap
2.97B
Income
98.93M
Revenue
994.1M
Book val./share
4.81
Cash/share
0.82
Dividend
0.1
Dividend %
0.83%
Employees
929
Optionable
No
Shortable
Yes
Earnings
27 Apr 2024
P/E
30.15
Forward P/E
13.59
PEG
-131.35
P/S
2.85
P/B
2.49
P/C
15.41
P/FCF
-46.79
Quick Ratio
0.97
Current Ratio
1.25
Debt / Equity
0.56
LT Debt / Equity
0.17
-
-
EPS (TTM)
0.43
EPS next Y
0.93
EPS next Q
-
EPS this Y
13.64%
EPS next Y
116.33%
EPS next 5Y
116.33%
EPS last 5Y
10.03%
Revenue last 5Y
9.39%
Revenue Q/Q
-21.25%
EPS Q/Q
96.51%
-
-
-
-
SMA20
46.61%
SMA50
7.86%
SMA100
10.94%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
9%
ROC
0.08%
Gross Margin
77%
Oper. Margin
11%
Profit Margin
10%
Payout
41%
Shs Outstand
227.58M
Shs Float
227.05M
-
-
-
-
Target Price
-
52W Range
7.59-15.38
52W High
-15.73%
52W Low
+80.57%
RSI
57.03
Rel Volume
0.43
Avg Volume
5.54M
Volume
2.38M
Perf Week
-9.78%
Perf Month
20.96%
Perf Quarter
-
Perf Half Y
4.55%
-
-
-
-
Beta
-0.165
-
-
Volatility
0.5%, 1.9%
Prev Close
1.2%
Price
12.64
Change
-1.94%
002873.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.05 | 3.42 | 3.11 | 3.97 | 4.69 | |
Net income per share | 0.31 | 0.32 | 0.3 | 0.41 | 0.48 | |
Operating cash flow per share | 0.21 | 0.15 | 0.73 | 0.51 | 0.33 | |
Free cash flow per share | 0.03 | -0.54 | 0.45 | 0.08 | -0.23 | |
Cash per share | 0.61 | 0.8 | 1.86 | 0.62 | 0.43 | |
Book value per share | 2.89 | 3.12 | 3.43 | 3.64 | 4.87 | |
Tangible book value per share | 2.51 | 2.61 | 2.89 | 3.08 | 4.23 | |
Share holders equity per share | 2.89 | 3.12 | 3.43 | 3.64 | 4.87 | |
Interest debt per share | 0.95 | 1.15 | 2.36 | 1.83 | 2.14 | |
Market cap | 1.84B | 1.95B | 2B | 3.53B | 3.36B | |
Enterprise value | 1.92B | 2.02B | 2.24B | 3.89B | 3.74B | |
P/E ratio | 25.99 | 27.27 | 27.59 | 35.47 | 30.11 | |
Price to sales ratio | 2.66 | 2.52 | 2.67 | 3.64 | 3.09 | |
POCF ratio | 38.75 | 57.74 | 11.39 | 28.39 | 44.29 | |
PFCF ratio | 261.57 | -15.92 | 18.6 | 189.61 | -62.9 | |
P/B Ratio | 2.8 | 2.75 | 2.42 | 3.96 | 2.97 | |
PTB ratio | 2.8 | 2.75 | 2.42 | 3.96 | 2.97 | |
EV to sales | 2.76 | 2.61 | 2.98 | 4.01 | 3.44 | |
Enterprise value over EBITDA | 18.98 | 18.6 | 20.48 | 24.41 | 22.99 | |
EV to operating cash flow | 40.3 | 59.9 | 12.72 | 31.26 | 49.37 | |
EV to free cash flow | 271.99 | -16.51 | 20.78 | 208.82 | -70.12 | |
Earnings yield | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | |
Free cash flow yield | 0 | -0.06 | 0.05 | 0.01 | -0.02 | |
Debt to equity | 0.32 | 0.36 | 0.68 | 0.48 | 0.43 | |
Debt to assets | 0.22 | 0.23 | 0.37 | 0.28 | 0.26 | |
Net debt to EBITDA | 0.73 | 0.67 | 2.15 | 2.25 | 2.37 | |
Current ratio | 2.1 | 1.77 | 1.58 | 1.33 | 1.23 | |
Interest coverage | 24.85 | 12.55 | 15.79 | 7.05 | 11.44 | |
Income quality | 0.68 | 0.48 | 2.37 | 1.24 | 0.65 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.31 | 0.23 | 0.36 | 0.3 | 0.31 | |
Sales general and administrative to revenue | 0.08 | 0.07 | 0.06 | 0.06 | 0.04 | |
Research and developement to revenue | 0.05 | 0.03 | 0.02 | 0.02 | 0.02 | |
Intangibles to total assets | 0.09 | 0.11 | 0.09 | 0.09 | 0.08 | |
Capex to operating cash flow | -0.85 | -4.63 | -0.39 | -0.85 | -1.7 | |
Capex to revenue | -0.06 | -0.2 | -0.09 | -0.11 | -0.12 | |
Capex to depreciation | -2.99 | -9.75 | -3.57 | -4.63 | -5.08 | |
Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0 | 0.01 | |
Graham number | 4.51 | 4.71 | 4.82 | 5.77 | 7.26 | |
ROIC | 0.07 | 0.07 | 0.05 | 0.08 | 0.07 | |
Return on tangible assets | 0.08 | 0.07 | 0.05 | 0.07 | 0.07 | |
Graham Net | 0.24 | 0.36 | -0.04 | -0.76 | -1.22 | |
Working capital | 329.49M | 257.36M | 299.24M | 145.59M | 115.24M | |
Tangible asset value | 570.74M | 590.98M | 696.35M | 752.75M | 980.05M | |
Net current asset value | 304.58M | 215.17M | 105.24M | -47.15M | -100.66M | |
Invested capital | 0.32 | 0.36 | 0.68 | 0.48 | 0.43 | |
Average receivables | 233.45M | 284.7M | 289.42M | 294.46M | 316.6M | |
Average payables | 36.36M | 36.56M | 37.79M | 54.85M | 80.28M | |
Average inventory | 74.37M | 88.13M | 90.43M | 102.8M | 151.06M | |
Days sales outstanding | 139.43 | 143.58 | 133.49 | 118.28 | 107.02 | |
Days payables outstanding | 106.1 | 69.09 | 98.93 | 117.75 | 141.21 | |
Days of inventory on hand | 205.94 | 211.12 | 191.68 | 215.51 | 270.62 | |
Receivables turnover | 2.62 | 2.54 | 2.73 | 3.09 | 3.41 | |
Payables turnover | 3.44 | 5.28 | 3.69 | 3.1 | 2.58 | |
Inventory turnover | 1.77 | 1.73 | 1.9 | 1.69 | 1.35 | |
ROE | 0.11 | 0.1 | 0.09 | 0.11 | 0.1 | |
Capex per share | -0.18 | -0.69 | -0.28 | -0.43 | -0.56 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.96 | 0.94 | 0.85 | 1.29 | 1.01 | |
Net income per share | 0.27 | 0.05 | 0.1 | 0.09 | 0.17 | |
Operating cash flow per share | 0.27 | 0.05 | 0.1 | -0.06 | 0.2 | |
Free cash flow per share | 0.13 | -0.06 | -0.04 | -0.16 | 0.15 | |
Cash per share | 0.51 | 0.43 | 0.47 | 0.52 | 0.82 | |
Book value per share | 5.74 | 4.87 | 4.7 | 4.71 | 4.81 | |
Tangible book value per share | 4.9 | 4.22 | 4.07 | 4.06 | 4.16 | |
Share holders equity per share | 5.74 | 4.87 | 4.7 | 4.71 | 4.81 | |
Interest debt per share | 2.42 | 2.12 | 2.24 | 2.55 | 2.72 | |
Market cap | 1.84B | 3.36B | 3.38B | 3.32B | 3.18B | |
Enterprise value | 2.18B | 3.75B | 3.81B | 3.81B | 3.64B | |
P/E ratio | 9.72 | 74.91 | 33.69 | 39.04 | 19.19 | |
Price to sales ratio | 5.35 | 15.38 | 16.2 | 10.46 | 12.72 | |
POCF ratio | 38.88 | 299.64 | 134.77 | -233.57 | 62.69 | |
PFCF ratio | 78.31 | -260.47 | -365.45 | -84.55 | 85.19 | |
P/B Ratio | 1.83 | 2.98 | 2.93 | 2.87 | 2.66 | |
PTB ratio | 1.83 | 2.98 | 2.93 | 2.87 | 2.66 | |
EV to sales | 6.32 | 17.15 | 18.27 | 12.02 | 14.59 | |
Enterprise value over EBITDA | 39.57 | 426.52 | 125.76 | 107.16 | 69.92 | |
EV to operating cash flow | 45.91 | 334.01 | 151.96 | -268.44 | 71.93 | |
EV to free cash flow | 92.47 | -290.35 | -412.06 | -97.17 | 97.74 | |
Earnings yield | 0.03 | 0 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0 | 0 | -0.01 | 0.01 | |
Debt to equity | 0.42 | 0.43 | 0.47 | 0.54 | 0.56 | |
Debt to assets | 0.26 | 0.26 | 0.29 | 0.31 | 0.32 | |
Net debt to EBITDA | 6.06 | 43.9 | 14.23 | 13.92 | 8.97 | |
Current ratio | 1.46 | 1.23 | 1.21 | 1.23 | 1.25 | |
Interest coverage | 15.37 | 0.99 | 6.97 | 8.47 | 11.17 | |
Income quality | 1 | 1 | 1 | -0.67 | 1.22 | |
Dividend Yield | 0.01 | 0 | 0 | 0.01 | 0 | |
Payout ratio | 0.48 | 0.48 | 0.14 | 1.28 | 0.11 | |
Sales general and administrative to revenue | 0.23 | -0.24 | 0.13 | -0.02 | 0.36 | |
Research and developement to revenue | 0.01 | 0.04 | 0.02 | 0.03 | 0.04 | |
Intangibles to total assets | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | |
Capex to operating cash flow | -0.5 | -2.15 | -1.37 | 1.76 | -0.26 | |
Capex to revenue | -0.07 | -0.11 | -0.16 | -0.08 | -0.05 | |
Capex to depreciation | -3.84 | -3.88 | -5.97 | -4.35 | 1.29 | |
Stock based compensation to revenue | -0.02 | 0.05 | 0 | 0.01 | -0.01 | |
Graham number | 5.9 | 2.3 | 3.29 | 3.03 | 4.25 | |
ROIC | 0.03 | 0.01 | 0.01 | 0.01 | 0.02 | |
Return on tangible assets | 0.03 | 0.01 | 0.01 | 0.01 | 0.02 | |
Graham Net | -0.98 | -1.22 | -1.21 | -1.31 | -1.16 | |
Working capital | 198.8M | 115.24M | 110.03M | 128.49M | 155.49M | |
Tangible asset value | 863.41M | 980.05M | 1B | 996.9M | 1.03B | |
Net current asset value | 1.47M | -100.66M | -108.24M | -131.53M | -102.55M | |
Invested capital | 0.42 | 0.43 | 0.47 | 0.54 | 0.56 | |
Average receivables | 350.29M | 357.12M | 310.92M | 345.63M | 392.68M | |
Average payables | 67.65M | 79.29M | 91.52M | 85.29M | 85.88M | |
Average inventory | 158.64M | 166.74M | 197.02M | 194.48M | 174.3M | |
Days sales outstanding | 103.22 | 131.4 | 130.6 | 110.2 | 143.07 | |
Days payables outstanding | 70.29 | 160.37 | 171.73 | 100.46 | 139.75 | |
Days of inventory on hand | 167.72 | 307.34 | 414.14 | 215.22 | 268.81 | |
Receivables turnover | 0.87 | 0.68 | 0.69 | 0.82 | 0.63 | |
Payables turnover | 1.28 | 0.56 | 0.52 | 0.9 | 0.64 | |
Inventory turnover | 0.54 | 0.29 | 0.22 | 0.42 | 0.33 | |
ROE | 0.05 | 0.01 | 0.02 | 0.02 | 0.03 | |
Capex per share | -0.14 | -0.1 | -0.14 | -0.1 | -0.05 |
002873.SZ Frequently Asked Questions
What is Guiyang Xintian Pharmaceutical Co.,Ltd. stock symbol ?
Guiyang Xintian Pharmaceutical Co.,Ltd. is a CN stock and trading under the symbol 002873.SZ
What is Guiyang Xintian Pharmaceutical Co.,Ltd. stock quote today ?
Guiyang Xintian Pharmaceutical Co.,Ltd. stock price is $12.64 today.
Is Guiyang Xintian Pharmaceutical Co.,Ltd. stock public?
Yes, Guiyang Xintian Pharmaceutical Co.,Ltd. is a publicly traded company.